Nephroblastoma
Conditions
Brief summary
The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
Detailed description
The study is based on results form 2 previous studies carried out by the GFAOP. This study aims to evaluate the capacity of units to follow the recommendations in the protocol. It will look mainly at treatment compliance and outcome for the children treated. The study will also evaluate the improvement in treatment compliance and reporting. This work will help the group to evaluate future needs in participating units and help us adapt treatment programmes to local conditions.
Interventions
OTHERData collection
Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
Sponsors
French Africa Pediatric Oncology Group
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment. .
Exclusion criteria
Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluating the follow up after treatment. | 5 Years | How many children alive or dead after treatment |
| Evaluation of the number of cases with stage IV disease. | 5 Years | By evaluating the initial clinical reports and later histological reports to confirm the stage. |
| Evaluating the treatment given. | 5 Years | Comparison of treatment given and recommended treatment. |
| Evaluation of the number of cases with local disease. | 5 years | By evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Why has treatment failed | 5 years | look at precision of reporting by comparing reports (histological and surgical) |
Countries
Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo, Madagascar, Mali, Senegal
Contacts
CONTACTBRENDA Ms MALLON, MSC
PRINCIPAL_INVESTIGATORFatou Binetou Ms DIAGNE AKONDE, Dr
French Africa Pediatric Oncology Group
Outcome results
None listed